Contact Customer Service or Scientific Support
Download our Catalog
Subscribe to eNewsletters
Now Available for On-Demand Viewing
This webinar considers technologies being employed to build advanced human liver culture platforms that display key features of global liver diseases such as non-alcoholic fatty liver disease, liver fibrosis, and hepatitis B viral infection, which are currently the subject of novel drug discovery by several major pharmaceutical companies. The use of primary human hepatocytes and other cell types of the liver (e.g. hepatic stellate cells) for building human liver platforms will be discussed as well as long-term cell characterization and drug validation data as appropriate. Finally, emerging trends will be discussed that will move the field forward towards alleviating the burden of liver disease on human patient populations.
Register to watch our webinar for an overview of complex models related to liver disease research.
Topics:
Register to watch
Speaker: Salman Khetani, Ph.D.
Associate Professor, Bioengineering
University of Illinois at Chicago
Dr. Salman Khetani, associate professor of Bioengineering at the University of Illinois at Chicago, is a recognized international expert and pioneer in the engineering of human liver platforms for drug development. He received his BS degree in Biomedical Engineering and Electrical Engineering from Marquette University, and then obtained his MS and PhD degrees in Bioengineering from the University of California at San Diego. After post-doctoral research at MIT, Dr. Khetani founded and directed research at Hepregen Corporation to commercialize his liver inventions. In 2011, Dr. Khetani returned to academia, first to Colorado State University and then to the University of Illinois at Chicago, to further develop human tissue models and explore their novel applications in drug development and regenerative medicine. Dr. Khetani’s 47+ publications have been cited more than 3000 times and have been funded by NIH, NSF, DOD, FDA, and major pharmaceutical companies.
Learn more about our Hepatocytes/ADMETox offerings.
